Toad venom is not legal in the United States when it contains psychoactive compounds, which is the form most people are asking about. The venom of the Sonoran Desert toad contains two substances, 5-MeO-DMT and bufotenine, that are both classified as Schedule I controlled substances under federal law. Possessing, distributing, or using the venom for its psychoactive effects carries the same legal weight as possessing other Schedule I drugs like LSD or psilocybin.
Federal Classification of Toad Venom Compounds
The two psychoactive chemicals in Sonoran Desert toad venom sit in the most restrictive category of the Controlled Substances Act. Bufotenine has been listed as Schedule I for decades. 5-MeO-DMT, the compound that drives most of the current interest in toad venom, was added to Schedule I by the DEA in a final rule that took effect on January 19, 2011. Before that date, 5-MeO-DMT existed in a legal gray area at the federal level.
Schedule I classification means the federal government considers these substances to have a high potential for abuse and no currently accepted medical use. The law covers “any material, compound, mixture, or preparation” containing any quantity of these chemicals. That language is broad enough to include raw toad venom, dried venom, and any preparation made from it. You don’t need to extract or purify the compound for it to be illegal. The venom itself, because it contains a Schedule I substance, falls under the statute.
Penalties for Possession
Because 5-MeO-DMT and bufotenine are Schedule I hallucinogens, possession without authorization is a federal crime. A first offense for simple possession of any Schedule I substance can carry up to one year in prison and a minimum fine of $1,000. Distribution or intent to distribute carries far steeper consequences, potentially ranging from five to 20 years depending on the quantity and circumstances. State charges can be filed on top of federal ones, and many states mirror federal scheduling in their own drug codes.
Wildlife Laws Add Another Layer
The legal question doesn’t stop at drug scheduling. The Sonoran Desert toad (Incilius alvarius) is the only toad species that produces enough 5-MeO-DMT to have psychoactive effects, and it lives in a narrow range across the southwestern U.S. and northwestern Mexico. Collecting or harassing the toad itself can violate wildlife protection laws.
In Arizona, where the toad is most commonly found, all amphibians are managed by the Arizona Game and Fish Department. It is unlawful to possess, kill, harass, hunt, or handle wildlife protected by state or federal law without proper permits. While the Sonoran Desert toad is not currently listed as endangered (the IUCN ranks it as Least Concern globally), Arizona regulates the collection of amphibians and requires a valid license for taking them from public waters. In California, the species is ranked as possibly extirpated from the state and carries a “Species of Special Concern” designation, which adds further restrictions on handling or collection.
Growing demand for toad venom has raised conservation concerns. Even where the species is globally secure, localized harvesting pressure can deplete populations in specific areas, which is one reason wildlife agencies have taken a closer look at enforcement.
State Decriminalization Efforts
Several states have explored decriminalizing certain psychedelics, but none have successfully removed penalties for 5-MeO-DMT specifically. California’s Senate Bill 58, which would have decriminalized possession of several psychedelics including DMT and psilocybin for adults 21 and older starting in 2025, was vetoed by Governor Newsom in October 2023. His veto message noted that the bill would decriminalize possession before recommended treatment guidelines were established.
Oregon decriminalized possession of small amounts of all drugs in 2020 but later reversed course. Colorado legalized certain psilocybin services but did not include 5-MeO-DMT or toad venom in that framework. As of now, no U.S. state has carved out a legal exception for toad venom or its primary psychoactive compound.
Legal Status Outside the U.S.
The legal picture shifts considerably outside U.S. borders. 5-MeO-DMT is not listed under the United Nations Convention on Psychotropic Substances, which means individual countries decide whether to regulate it. In Canada, 5-MeO-DMT is not a controlled substance. Mexico also does not schedule the compound, and retreat centers offering toad venom ceremonies have operated there openly, particularly in the Sonoran region where the toads are native.
This international patchwork is a major reason toad venom retreats have proliferated in Mexico and parts of Central and South America. Some U.S. residents travel to these countries specifically to participate in guided ceremonies, which is legal in the host country but can create complications if participants bring any substance back across the border.
Clinical Research and FDA Trials
Despite the Schedule I classification, researchers can obtain special authorization to study 5-MeO-DMT. A Phase 1 clinical trial registered with the FDA tested a synthetic (non-toad-derived) form of 5-MeO-DMT in healthy volunteers, measuring its safety and how the body processes the drug. That trial completed in September 2023. The use of synthetic 5-MeO-DMT in research is significant because it sidesteps both the wildlife concerns and the variability of natural toad venom.
If clinical trials eventually demonstrate therapeutic value, the compound could be rescheduled, as happened with esketamine for depression. That process takes years and requires multiple phases of successful trials. For now, the Schedule I status remains firmly in place, and no FDA-approved medical use exists for either toad venom or its isolated compounds.